Scott Kopetz, MD, PhD, FACP, discusses the updated survival data from the BEACON CRC study in BRAF V600E–mutated metastatic colorectal cancer.
Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the updated survival data from the BEACON CRC study in BRAF V600E—mutated metastatic colorectal cancer (CRC).
In the phase 3 BEACON CRC study, investigators evaluated the triplet regimen of encorafenib (Braftovi) plus binimetinib (Mektovi) and cetuximab (Erbitux) and the doublet of encorafenib plus cetuximab versus investigator’s choice of irinotecan plus cetuximab or FOLFIRI plus cetuximab in patients with BRAF V600E—mutated metastatic CRC whose disease had progressed after 1 or 2 prior regimens in the metastatic setting.
The updated survival data that was presented at the 2020 ASCO Virtual Scientific Program includes 6 months of additional follow-up and response data for all patients randomized in the trial, says Kopetz. Previously, investigators had reported only the first half of the patients as per the pre-planned analysis. This report includes updated survival data with more mature follow-up.
Results showed a median overall survival (OS) in both of the experimental arms was 9.3 months, which was superior to the 5.4 months reported in the control arm. In addition, objective response rates (ORR) in the triplet and the doublet arms were 26.8% and 19.5%, respectively, and 1.8% in the control arm, concludes Kopetz.